News

Patient-Focused SUNRISE-PD Trial Overview and Benefits Revealed

Patient-Focused SUNRISE-PD Trial Overview and Benefits Revealed

Patient-Centric Design in SUNRISE-PD Trial

In a notable presentation at the Advanced Therapeutics in Movement & Related Disorders Congress, BioVie Inc. (NASDAQ: BIVI) showcased its commitment to innovative and patient-centric approaches in clinical trial design. The SUNRISE-PD Phase 2 trial, focusing on bezisterim (NE3107), emphasizes accessibility for patients suffering from Parkinson’s disease (PD), particularly those facing obstacles to conventional trial participation.

Breaking Barriers for Parkinson’s Disease Patients

Parkinson's disease often presents numerous challenges in accessing specialized care. This can include delayed diagnoses, limited mobility, and geographical limitations that hinder participation in clinical trials. The SUNRISE-PD trial aims to alleviate these challenges by incorporating a hybrid, decentralized design, allowing participants to conduct visits either from the comfort of their homes or in clinical settings. This flexibility is crucial for improving access and encouraging broader participation in PD research.

Innovative Therapeutic Approaches

Cuong Do, President and CEO of BioVie, commented on the significance of the SUNRISE-PD trial, stating it represents a pioneering approach in clinical trial design by meeting patients where they are. This model combines the innovative therapeutic potential of bezisterim with a decentralized structure, creating an inclusive environment that encourages participant engagement while maintaining scientific integrity.

Engagement and Support for Patients

The trial targets individuals aged 41 to 80 who have been diagnosed with early-stage PD within the last four years and have not yet begun treatment with standard medications like carbidopa/levodopa. Through collaborations with esteemed organizations, BioVie is actively enhancing awareness and outreach across the U.S., facilitating patient enrollment in this groundbreaking study.

Utilizing Technology to Enhance Trials

SUNRISE-PD employs a flexible design that includes in-home visits conducted by study nurses under the supervision of neurologists, utilizing video conferencing for oversight. Additionally, the assessments of motor symptoms are performed remotely using a modified version of the MDS-UPDRS Part III scale evaluated by a centralized committee. This comprehensive approach ensures the integrity of data collection while prioritizing participant convenience.

Bezisterim: A Novel Treatment Option

Bezisterim is an orally available compound designed to cross the blood-brain barrier, targeting inflammation and insulin sensitivity, with previous trials indicating notable improvements in both motor and non-motor symptoms of PD. This medication aims to address the underlying biological processes contributing to the progression of Parkinson's disease, offering a potential method to modify its long-term impact.

Details of the SUNRISE-PD Presentation

The upcoming presentation at the Congress will provide detailed insights into the SUNRISE-PD study. Here are the specifics:

  • Title: SUNRISE-PD: An Ongoing, Hybrid, Decentralized Phase 2 Study of Bezisterim in Early Parkinson’s Disease
  • Poster Session: 11:30 am to 12:30 pm, Friday
  • Authors: A team of leading researchers and experts
  • Poster Position: P 49
  • Display Duration: From 7:00 am Friday through 2:00 pm Sunday

Understanding Parkinson’s Disease

Parkinson’s disease is a progressive disorder that significantly impacts movement. It stems from the degeneration of dopamine-producing neurons, leading to core symptoms such as tremors, rigidity, and bradykinesia. Beyond motor symptoms, patients often experience non-motor challenges, including cognitive impairments and mood disorders, which can severely affect daily life.

Exploring the Role of Bezisterim

Research is increasingly uncovering the influence of chronic inflammation and insulin resistance on the development of Parkinson’s disease. Bezisterim's multifaceted mode of action positions it as a promising candidate for addressing these factors effectively. The existing data from past trials underscores its potential for enhancing the quality of life among patients experiencing both motor and non-motor symptoms.

About BioVie Inc.

BioVie Inc., under the stock ticker NASDAQ: BIVI, focuses on developing cutting-edge therapies for neurodegenerative disorders such as Alzheimer's disease, Parkinson’s disease, and long COVID. With their innovative compound, bezisterim, the company is on the forefront of research aimed at tackling the challenges posed by these debilitating conditions while exploring avenues for new treatments.

Frequently Asked Questions

What is the SUNRISE-PD trial?

The SUNRISE-PD trial is a Phase 2 clinical trial evaluating the effects of bezisterim in individuals with early-stage Parkinson’s disease, designed to enhance accessibility and patient participation.

How does bezisterim work?

Bezisterim is an anti-inflammatory, insulin-sensitizing compound that aims to improve both motor and non-motor symptoms in individuals with Parkinson’s disease.

What are the eligibility criteria for the SUNRISE-PD trial?

Participants must be between 41 and 80 years old, diagnosed with early-stage Parkinson's in the last four years, and not yet on treatment with standard therapies.

Where can I find more information about the SUNRISE-PD trial?

For additional information, including details on participation, visit www.SUNRISEPD.com.

Who is leading BioVie Inc.?

BioVie is led by Cuong Do, the President and CEO, who emphasizes patient accessibility in clinical trial designs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 81

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 185

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 236

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 36

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Fannie Mae Reports Strong Financial Update for Third Quarter

Updated Category News Views 81

Fannie Mae Reports Impressive Third Quarter Financial Results Fannie Mae has recently announced its financial performance for the third quarter of the year, marking a significant achievement with a net income of $4 billion. This statement underscores Fannie Mae's resilience and strategic efforts in the ongoing housing market. These results were disclosed alongside the...

Continue Reading
Willdan's Innovative Energy Design Assistance for Seattle

Updated Category News Views 51

Willdan Partners with Seattle for Energy Design Innovation Willdan Group, Inc. (NASDAQ: WLDN) is thrilled to announce that it has entered into a significant four-year contract to implement the Seattle City Light Energy Design Assistance Program. This initiative is a vital step toward enhancing sustainability in the development of multifamily and commercial buildings. With...

Continue Reading
Nikola Corporation Achieves Record Hydrogen Truck Deliveries

Updated Category News Views 79

Nikola Corporation Reports Impressive Third Quarter Results Nikola Corporation (NASDAQ: NKLA) has announced its third-quarter results, showcasing remarkable progress in its hydrogen fuel cell electric vehicle (FCEV) segment. The company registered a record 88 wholesale deliveries of hydrogen FCEVs, marking a 22% increase from the previous quarter. This significant growth...

Continue Reading
Tempest Therapeutics (TPST) Faces Major Stock Decline Today

Updated Category News Views 295

Understanding the Significant Decline of Tempest Therapeutics Stock Tempest Therapeutics Inc (NASDAQ: TPST) is experiencing a notable decrease in share value today. The sharp decline follows the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Understanding the implications of this acquisition is crucial for investors and...

Continue Reading
FHU's Leadership Program Graduates First Cohort

Updated Category News Views 35

A New Dawn for School Leadership In the world of education, fresh thinking and dynamic leadership can often feel as profound as breakthroughs in any field. Today, we're celebrating a step in that direction. Freed-Hardeman University (FHU) in the heartland of Tennessee is marking a grand milestone. The university just rolled out its first cohort of graduates from the...

Continue Reading